New Blood Test Shows 95% Accuracy in Diagnosing Endometriosis
For the estimated 1 in 10 women living with endometriosis, receiving a diagnosis has traditionally involved years of dismissed symptoms, numerous doctor visits, and often an invasive surgical procedure. However, recent developments indicate that this may change. The U.K.'s National Institute for Health and Care Excellence has approved the rollout of two new tests for endometriosis—one using saliva and another employing electric sensors attached to the abdomen, providing immediate results. These tests are part of an evidence collection phase following encouraging trial outcomes.
In addition, a new study published in the European Journal of Endocrinology suggests that a simple blood test could soon serve as a reliable diagnostic tool for endometriosis. Researchers explored whether hormone levels in the blood could provide a less invasive diagnostic route. Endometriosis occurs when tissue similar to the uterine lining grows outside the uterus, leading to chronic pain, inflammation, and potential fertility issues. Despite its prevalence, diagnosis has remained challenging, with laparoscopy being the only definitive method, requiring general anesthesia.
The study involved 159 women with laparoscopically confirmed endometriosis and 57 women without the condition. Rather than focusing solely on estrogen, the hormone most commonly associated with endometriosis, researchers measured a broad range of androgens in blood samples. They developed a predictive model designed to identify endometriosis based on these measurements.
The analysis revealed significant hormonal differences between women with and without endometriosis. Women diagnosed with the condition exhibited elevated levels of several androgens, including DHEA, androstenedione, testosterone, and particularly 11-ketotestosterone. Concurrently, certain androgen precursor metabolites were found to be lower in women with endometriosis, indicating a shift in androgen metabolism towards producing more 11-ketotestosterone rather than its precursors.
This androgen, which has not received much attention in women's health research, appears to play a crucial role in endometriosis. The combination of elevated active androgens and decreased precursors created a hormonal profile that effectively distinguished women with endometriosis from those without.
When the predictive model was applied to a separate, blinded group, it identified endometriosis with over 95% accuracy, a significant improvement over current non-surgical screening tools such as the CA-125 blood marker, which have lower accuracy and are not reliable for routine diagnosis.
The implications of such a precise, non-invasive diagnostic tool are profound. Currently, the average time from symptom onset to a confirmed diagnosis of endometriosis can span several years, during which many women face undertreatment, misdiagnosis, or are told their pain is normal. A blood test with this level of accuracy could enable earlier diagnosis and treatment, potentially leading to better long-term health outcomes. It could also decrease the number of women undergoing unnecessary surgeries to obtain a diagnosis.
Although this research is in its early stages and the blood test is not yet available in clinical settings, it validates the complexity of endometriosis biology beyond the estrogen-centric view and suggests that improved diagnostic options may be forthcoming. For those experiencing symptoms such as chronic pelvic pain, painful periods, or unexplained fertility challenges without a clear diagnosis, this research serves as a reminder that their experiences are valid and that scientific advancements are progressing. In the meantime, consulting with a specialist experienced in endometriosis remains crucial. Keeping a detailed symptom log and seeking second opinions can be vital steps in the journey toward diagnosis and treatment.




